Ads blast Merck on AIDS drug prices in Mexico

Share this article:
Ads blast Merck on AIDS drug prices in Mexico
Ads blast Merck on AIDS drug prices in Mexico
The AIDS Healthcare Foundation launched a print ad aimed at shaming Merck in its own neighborhood for the prices it charges for AIDS drug Stocrin (Sustiva) in Mexico.

The nonprofit, a frequent nemesis of the pharma industry which has previously run ads slamming drug companies for how they price and market their drugs, ran the ad in The Courier News of Somerset County, NJ, near Merck's US corporate headquarters. With the tagline “Shame on Merck,” the ad copy reads in part: “Merck's Stocrin (efavirenz) is the backbone of many standard antiretroviral drug regimens. AIDS advocates question why Stocrin costs approximately $140 USD in Honduras, yet Merck charges $893 USD for Stocrin in Mexico. Advocates and HIV/AIDS patients insist Merck must match its lowest available price of Stocrin in other Latin American countries in Mexico as well.”

The ads, timed to coincide with the 2008 International AIDS conference in Mexico, will also appear in The Hunterdon County Democrat, The Village Voice and The Washington Blade.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...